



**SDI Review Form 1.6**

Journal Name:	<b><u>British Journal of Medicine and Medical Research</u></b>
Manuscript Number:	<b>2013_BJMMR_8559</b>
Title of the Manuscript:	<b>Hepatic Antioxidant Effect of Paroxetine in Rats Exposed to Chronic Restraint Model</b>
Type of the Article	

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b><u>Compulsory</u></b> REVISION comments	<p>Page 1 Line 10-13: Abstract: The authors assumption is "Paroxetine reduces oxidative stress". Whether psychological stress is directly responsible for hepatic damage or CNS damage indirectly involves with additive effect like oxidative damage caused by comorbid psychoactive substance abuse is a matter of debate.</p> <p>Page 1 Line 22-26: Abstract: Even 3-5 times of range of Serum AST &amp; ALT are normal. So raised value of AST &amp; ALT from baseline and calculation of p value especially with a small sample size like the present study has to be adjusted with appropriate statistical methods.</p> <p>Page 3 Line 58-61: How the Chronic restraint model in albino rats and why the 6 hrs restraint is chosen not explained by researchers. Whether in present day the depression in human subjects can be compared with absolute restraint model in albino rats has not been justified by the authors.</p> <p>Page 7: Line 137-140: Why paroxetine is chosen by authors? Whether they have worked similarly with other SSRIs/SNRIs?</p> <p>Page 12 Line 216-227: May be written in Introduction, not appropriate in discussion section.</p>	



**SDI Review Form 1.6**

<b><u>Minor</u></b> REVISION comments		
<b><u>Optional/General</u></b> comments		

**Note: Anonymous Reviewer**